Subsidiary company of Zhongguancun (000931.SZ) Beijing Huasu Pharmaceutical Co., Ltd. passes consistency evaluation for Naproxen hydrochloride tablets.

China Fortune Finance APP news, Zhongguancun (000931.SZ) announced that recently, its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter referred to as "Beijing Huasu"), received the "Drug Supplementary Application Approval Notification" (Notification number: 2025B04969) issued by the National Medical Products Administration. It was learned that the "Naquidone Hydrochloride Tablets" (Specification: 50mg) produced by Beijing Huasu has passed the evaluation of generic drug quality and efficacy consistency.